WO2023201511A1 - 一种用于早期诊断阿尔茨海默症的生物标志物及其用途 - Google Patents

一种用于早期诊断阿尔茨海默症的生物标志物及其用途 Download PDF

Info

Publication number
WO2023201511A1
WO2023201511A1 PCT/CN2022/087570 CN2022087570W WO2023201511A1 WO 2023201511 A1 WO2023201511 A1 WO 2023201511A1 CN 2022087570 W CN2022087570 W CN 2022087570W WO 2023201511 A1 WO2023201511 A1 WO 2023201511A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
peripheral blood
interleukin
neurodegenerative diseases
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/087570
Other languages
English (en)
French (fr)
Inventor
陈宇
屈雪琪
毛梦
柴岳
陈静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Institute of Advanced Technology of CAS
Original Assignee
Shenzhen Institute of Advanced Technology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Institute of Advanced Technology of CAS filed Critical Shenzhen Institute of Advanced Technology of CAS
Priority to PCT/CN2022/087570 priority Critical patent/WO2023201511A1/zh
Publication of WO2023201511A1 publication Critical patent/WO2023201511A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the invention belongs to the field of biotechnology, and specifically relates to a biomarker for early diagnosis of Alzheimer's disease and its use.
  • AD Alzheimer’s disease
  • a ⁇ oligomeric ⁇ -amyloid
  • NFTs neurofibrillary tangles
  • pathogenic hypotheses include: A ⁇ aggregation hypothesis, Tau protein abnormality hypothesis, cholinergic hypothesis, neuroinflammation hypothesis, etc. Due to the complex etiology of the disease, none of the above hypotheses can effectively elucidate its pathogenesis, and research on its treatment drugs is progressing slowly. Currently, there is still a lack of drugs or methods to cure AD in the world. Anti-A ⁇ immunotherapy has always been a research and development hotspot. However, due to the difficulty of drug development, most of the drugs currently entering Phase III clinical trials have ended in failure. Therefore, it is urgent to study the pathological mechanisms of AD from multiple angles and to find early biodetection markers.
  • AD Alzheimer's disease
  • the current diagnostic method for AD is mainly combined diagnosis, which mainly includes: neuropsychological assessment, cognitive impairment test; PET scan of brain senile plaques and Tau protein; brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) markers, A ⁇ Deposition, phosphorylated tau protein detection, etc.
  • MRI brain magnetic resonance imaging
  • CSF cerebrospinal fluid
  • AD mild cognitive impairment
  • MCI mild cognitive impairment
  • early molecular screening technologies for AD include positron emission computed tomography (PET) and cerebrospinal fluid A ⁇ molecular level detection.
  • PET positron emission computed tomography
  • cerebrospinal fluid A ⁇ molecular level detection The former requires a certain dose of radioactive material to be injected into the subject; the latter requires a large amount of damage and is easy to cause. Cause surgical infection.
  • the reliability of these diagnostic technologies for early diagnosis of AD is also unstable, making it difficult to be used for early AD screening.
  • the prevention, diagnosis, treatment and rehabilitation of AD are currently recognized problems in the world. The development of new markers and simple detection methods for early diagnosis of AD is one of the important directions for the diagnosis and treatment of AD in the future.
  • the present invention aims to provide a biomarker for early diagnosis of Alzheimer's disease and its use.
  • Neuroinflammation is one of the main pathological features in the brain of AD patients, and the inflammatory process promotes the progression of A ⁇ pathology and Tau pathology. Therefore, neuroinflammation plays a key role in the occurrence and development of AD, and the treatment of neuroinflammation in the brain has become a new hot spot in the treatment of AD at this stage. Targeting this key molecule that regulates early neuroinflammation is regarded as a potential new therapeutic target for AD intervention.
  • a large number of studies have shown that circulating immune cells in the blood play a crucial role in maintaining central nervous system homeostasis and mediating immune responses to neurological diseases.
  • AD adaptive peripheral immune cell subsets
  • cytotoxic molecules a group of adaptive peripheral immune cell subsets are found in the brains of AD patients and in the hippocampus of AD mouse models. They can release inflammatory factors and cytotoxic molecules, promote inflammatory reactions in the brain, and lead to neuronal dysfunction. Increased pro-inflammatory cytokines, immune cell infiltration and glial cell activation are important neuroinflammatory responses in AD.
  • the present invention detects the correlation between the levels of inflammatory factors in peripheral blood, immune cell subpopulation changes and the severity of neuroinflammation in the brain at different stages of AD disease, thereby determining the changes in the expression levels of inflammatory factors in peripheral blood and the number of immune cell subpopulations. Change the directive role in the AD process.
  • a first aspect of the present invention provides the use of one or more of peripheral blood interleukin-6, peripheral blood CD8 + T cells and peripheral blood CD4 + T cells as biomarkers for early diagnosis of neurodegenerative diseases.
  • the neurodegenerative disease is Alzheimer's disease.
  • a second aspect of the present invention provides the use of one or more of peripheral blood interleukin-6, peripheral blood CD8 + T cells and peripheral blood CD4 + T cells in the preparation of products for early diagnosis of neurodegenerative diseases.
  • the products include: products for detecting the expression level of interleukin-6 in peripheral blood to diagnose neurodegenerative diseases through enzyme-linked immunosorbent assay, real-time fluorescence quantitative PCR or RT-PCR; and/or through flow cytometry analysis or immunoassay A product that detects changes in the number of peripheral blood CD8 + T cells and/or peripheral blood CD4 + T cells using fluorescent staining to diagnose neurodegenerative diseases.
  • the neurodegenerative disease is Alzheimer's disease.
  • the third aspect of the present invention provides the use of one or more of peripheral blood interleukin-6, peripheral blood CD8 + T cells and peripheral blood CD4 + T cells as drug targets for neurodegenerative diseases.
  • the neurodegenerative disease is Alzheimer's disease.
  • a fourth aspect of the present invention provides a method for early diagnosis of neurodegenerative diseases, which includes the following steps:
  • Detect the expression level of interleukin 6 and/or the number of CD8 + T cells and/or the number of CD4 + T cells in peripheral blood based on changes in the expression level of interleukin 6 and/or the number of CD8 + T cells in peripheral blood
  • To determine whether you are suffering from a neurodegenerative disease is based on the increase in the expression of interleukin 6 in peripheral blood and/or the severity of abnormalities in CD4 + T cells and/or CD8 + T cells. Determine the progression of neurodegenerative diseases;
  • the early diagnosis method also includes: detecting the expression level of interleukin 6 and/or the number of CD8 + T cells in the cerebrospinal fluid, and based on the changes in the expression level of interleukin 6 and/or the number of CD8 + T cells in the cerebrospinal fluid To determine whether you are suffering from a neurodegenerative disease, the progression of the neurodegenerative disease can be determined based on the increased expression level of interleukin 6 in the cerebrospinal fluid and/or the severity of CD8 + T cell abnormalities;
  • Neurodegeneration occurs when the expression level of interleukin-6 in the cerebrospinal fluid increases and/or the number of CD8 + T cells increases.
  • diagnosis is made based on changes in the expression level of interleukin-6 and the number of CD8 + T cells in peripheral blood;
  • diagnosis is made based on changes in the expression level of interleukin 6, changes in the number of CD8 + T cells, and changes in the number of CD4 + T cells in peripheral blood;
  • diagnosis is made based on changes in the expression level of interleukin-6 in peripheral blood, changes in the number of CD8 + T cells in peripheral blood, and changes in the number of CD8 + T cells in cerebrospinal fluid;
  • peripheral blood is obtained from humans or mice.
  • the neurodegenerative disease is Alzheimer's disease.
  • the above-mentioned use or the above-mentioned early diagnosis method is used in screening drugs for treating neurodegenerative diseases.
  • the drug for treating neurodegenerative diseases inhibits the expression of interleukin-6 in peripheral blood and/or reduces the number of CD8 + T cells and/or increases the number of CD4 + T cells in peripheral blood.
  • the neurodegenerative disease is Alzheimer's disease.
  • the sixth aspect of the present invention provides the above-mentioned use or the application of the above-mentioned early diagnosis method in screening new biomarkers or new drug targets for neurodegenerative diseases.
  • new biomarkers or new drug targets affect the expression level of interleukin 6 and/or the number of CD8 + T cells and/or the number of CD4 + T cells in peripheral blood.
  • the neurodegenerative disease is Alzheimer's disease.
  • the present invention achieves diagnosis of early AD based on changes in immune cells and immune molecules in peripheral circulation, and specifically provides inflammatory factor IL-6, peripheral circulation immune cell subgroups CD8 + T cells and helper CD4 + T cells as markers for early diagnosis of AD.
  • Cells can directly detect peripheral blood samples to determine the body's inflammation level and enable early screening of AD.
  • the advantage is that clinical diagnosis of the occurrence and development of AD by detecting biomarkers in blood not only reduces the diagnostic cost, but is also easy to operate, avoids the risk of central infection during brain sampling, is highly acceptable to patients, and is relatively easy to perform. Large-scale screening of diseases improves the efficiency of detection and increases the accuracy of results, and has practical application value.
  • the invention can be used to guide clinical screening, research on the pathogenesis of AD, screening of AD therapeutic drugs, and screening of new biomarkers and potential new drug targets for AD, and has broad application prospects.
  • FIG. 1 IL in peripheral blood of 3-month-old (3M), 6-month-old (6M), 9-month-old (9M) and 12-month-old (12M) wild-type mice (WT) and APP/PS1 mice (AD) -6 expression level changes (*p ⁇ 0.05).
  • A. The position of the brain slice taken in the brain atlas.
  • B. Shows the microglia surface marker Iba1, T cell surface marker CD8, and cell nuclear marker DAPI in brain tissue sections at different ages.
  • C Statistical results of brain infiltration of CD8+ T cells in WT and AD mice of different ages.
  • the present invention is mainly carried out in the APP/PS1 mouse model (hereinafter referred to as the AD mouse model).
  • the AD mouse model is one of the ideal animal models for simulating AD disease and is widely used in research on the pathogenesis of AD.
  • the present invention takes AD mouse models of different months of age as the research object, and uses brain tissue immunofluorescence staining technology, total RNA extraction technology, qRT-PCR technology, enzyme-linked immunosorbent assay (ELISA) of peripheral serum, etc. Comparison between the type (wild type littermate) and the diseased group (APP/PS1 transgenic mice, AD), the inflammatory factor IL-6 and cytotoxic CD8 + T cells and helper CD4 + T cells in peripheral blood were compared.
  • AD transgenic mice are related to the development of brain inflammation. Based on this, the present invention provides reliable evidence that changes in the expression level of the inflammatory factor IL-6 and changes in the number of cytotoxic CD8 + T cells and helper CD4 + T cells in peripheral blood can be used as molecular markers for early diagnosis of AD: 3-month-old AD
  • the mice correspond to the patient's disease course and are about to enter the mild intellectual impairment (MCI) stage.
  • MCI mild intellectual impairment
  • the 6-month-old AD mice have clear characteristics of AD symptoms.
  • mice and APP/PS1 mouse models were from Jackson Laboratory in the United States;
  • Paraformaldehyde was purchased from Sigma-aldrich, item number: 158127;
  • the embedding agent OCT was purchased from SAKURA, item number: 4583;
  • Iba1 primary antibody was purchased from Wake Company, product number: 019-19741;
  • CD8 primary antibody was purchased from Invitrogen, product number: 14-0195-82;
  • DAPI was purchased from Thermo Scientific Company, item number: 62248;
  • Fluorescent secondary antibodies were purchased from Thermo scientific;
  • Red blood cell lysate was purchased from BD Biosciences, product number: 555899;
  • Horse serum was purchased from Gibco Company, product number: 26050088;
  • Fetal bovine serum was purchased from Life Technologies, product number: 16050-122;
  • DAPI was purchased from Thermo Scientific Company, item number: D1306;
  • DPBS was purchased from Sigma Company, item number: D8662-24*500ML;
  • Trizol was purchased from Invitrogen Company, item number: 15596026;
  • the reverse transcription kit was purchased from Thermo scientific, product number K1622;
  • Real-time fluorescence quantitative PCR kit was purchased from Thermo scientific, catalog number 4368706;
  • the ELISA kit was purchased from R&D, product number: M6000B.
  • Example 1 Detection of the expression level of inflammatory factor IL-6 in peripheral blood
  • This example uses an ELISA kit to detect the expression levels of interleukin 6 (IL-6) in the peripheral blood of 3-month-old and 6-month-old wild-type mice and APP/PS1 mice respectively.
  • the steps are as follows:
  • mice were anesthetized with isoflurane gas, the blood samples of the mice were collected by fundus blood sampling into 1.5 mL sterilized EP tubes, and the necks were cut off quickly with scissors. The mice were killed head-on, and the serum was isolated as follows:
  • washing liquid dilute 1:25 with deionized water to the working concentration.
  • IL-6 standard Dilute the 5000pg/mL standard provided in the kit with calibration diluent 1:10 in a new EP tube to a 500pg/mL standard, and then dilute to the respective concentrations. Standards for 250pg/mL, 125pg/mL, 62.5pg/mL, 31.3pg/mL, 15.6pg/mL and 7.81pg/mL.
  • PBMCs peripheral blood mononuclear cells
  • This example performs flow cytometry analysis on peripheral blood mononuclear cells (PBMCs) of 6-month-old and 9-month-old wild-type mice and APP/PS1 mice. The steps are as follows:
  • PBMCs peripheral blood mononuclear cells
  • this example selected mice at the early stage of AD: 3 months old (3M) and 6 months old (6M) to conduct PBMCs T lymphocyte subpopulation flow cytometry. Analysis, the results are shown in Figure 2.
  • Flow cytometry analysis showed that compared with WT mice, in the peripheral blood of 6-month-old AD mice, the expression of helper T cells (CD4 + T cells) was significantly reduced, and the expression of cytotoxic T cells (CD8 + T cells) was significantly reduced. Increased levels indicate that immune cells in the peripheral circulation can exert an immunoregulatory effect on neuroinflammation in the AD brain. Revealing that CD8 + T cells can be used as peripheral circulating biomarkers for early AD diagnosis during AD progression.
  • This example uses an immunofluorescence staining kit to stain the brain tissue of wild-type mice and APP/PS1 mouse models (AD mouse models) for CD8, Iba1 and DAPI.
  • the steps are as follows:
  • mice were anesthetized by intraperitoneal injection of chloral hydrate. After deep anesthesia, they were fixed on a surgical board and placed in a dissection tray. The brains were removed from the posterior end and soaked and fixed with paraformaldehyde for 24 hours.
  • mice Use PBS at 4°C to perfuse mice, 20mL each, and then use 4% paraformaldehyde at 4°C (weigh 40g of paraformaldehyde and dissolve it in a glass container filled with 500mL of DEPC water) , continue to heat and magnetically stir to 60°C to form a milky white suspension.
  • Example 4 Detection of expression level of inflammatory factor IL-6 in cerebrospinal fluid
  • mice After the mice were anesthetized, their heads were fixed on the orientation device.
  • When collecting cerebrospinal fluid wipe the skin on the back of the rat's neck with wet gauze, cut off the back hair, expose the skin and disinfect it, use a scalpel to make a longitudinal incision (about 1cm) along the longitudinal axis, and use scissors to bluntly separate the back of the neck. muscle.
  • the deepest layer of muscle attached to the bone was scraped away with the back of a scalpel to expose the atlanto-occipital membrane.
  • a needle is inserted through the foramen magnum to directly extract cerebrospinal fluid. After the extraction is complete, the outer muscles and skin are sutured. Sulfonamide powder can be sprinkled on the incision to prevent infection.
  • an equal amount of sterilized saline should be injected to maintain the original pressure in the cerebrospinal cavity.
  • ELISA was performed on the cerebrospinal fluid of 3-month-old (3M) and 6-month-old (6M) wild-type mice (WT) and APP/PS1 mice (AD) to determine the level of IL-6 expression as the disease progresses.
  • the experimental steps are the same as those in Example 1.
  • IL-6 expression levels in the cerebrospinal fluid of 3-month-old (3M) and (6M) wild-type mice (WT) and APP/PS1 mice (AD) are shown in Figure 4.
  • WAT wild-type mice
  • AD mice showed significantly elevated IL-6 expression levels compared with WT mice at both 2 months of age. This shows that IL-6 is involved in the disease process caused by AD in the early stages of AD and can be used as a cerebrospinal fluid detection biomarker for early AD diagnosis.
  • Example 5 Detection of expression levels of inflammatory factor IL-6 in cerebral cortex and hippocampus
  • This example uses a real-time fluorescence quantitative PCR kit to measure the expression levels of IL-6 in the cerebral cortex (cortex) and hippocampus (hippocampus) of 3-month-old and 6-month-old wild-type mice and APP/PS1 mice respectively. To perform the test, the steps are as follows:
  • reaction mixture II according to the following system.
  • the system is as follows:
  • reaction mixture I to reaction mixture II, mix quickly for 5 seconds, incubate at 70°C for 5 minutes, then incubate on ice for 2 minutes, and perform reverse transcription according to the following procedure:
  • the obtained cDNA template was stored at -20°C for later use.
  • reaction system is as follows:
  • the sequence of the forward primer is shown in SEQ ID No.1
  • the sequence of the reverse primer is shown in SEQ ID No.2.
  • SEQ ID No.2 ctgtgaagtctcctctccgg.
  • Cyclic amplification 95°C, 15s; 60°C, 1min; 70°C, 1min; cycle 40 times;
  • the rate of heating and cooling during the entire process is 1.6°C/s.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

用于早期诊断阿尔茨海默症的生物标志物及其用途，具体为外周血白细胞介素6、外周血CD8 +T细胞和外周血CD4 +T细胞中的一种或几种作为早期诊断神经退行性疾病的生物标志物。神经退行性疾病的早期诊断方法，根据外周血中白细胞介素6表达水平的变化和/或CD8 +T细胞数量的变化和/或CD4 +T细胞数量的变化判断是否罹患神经退行性疾病，根据外周血中白细胞介素6表达上升水平和/或CD4 +T细胞和/或CD8 +T细胞异常情况的严重程度判断神经退行性疾病进程。通过检测血液中生物标志物进行AD发生发展的临床诊断，成本低，易操作，风险小，易于大规模筛查，具有实际应用价值。

Description

一种用于早期诊断阿尔茨海默症的生物标志物及其用途 技术领域
本发明属于生物技术领域，具体涉及一种用于早期诊断阿尔茨海默症的生物标志物及其用途。
背景技术
阿尔茨海默症(Alzheimer’s disease,AD)是和年龄相关的中枢神经退行性疾病，是老年痴呆中最常见的类型。在临床上，AD病人以进性记忆减退、认知功能障碍、语言障碍、记忆力减退、执行能力下降和人格方面的改变等表现，约占所有痴呆的60％-70％。最新数据表明，目前全球有5000万痴呆患者，到2050年，在全世界范围内将增加3倍。AD患者脑内典型的病理特征是寡聚β淀粉样蛋白(Aβ)斑块聚集、Tau蛋白过度磷酸化形成的神经元纤维缠结(NFT)和脑内广泛的炎症反应。目前，被广泛接受的致病假说有：Aβ聚集假说、Tau蛋白异常假说、胆碱能假说、神经炎症假说等。由于该病的病因复杂，上述假说均不能有效阐明其发病机制，且其治疗药物研究进展缓慢，目前全球仍缺乏治愈AD的药物或方法。一直以来，抗Aβ的免疫治疗是也研发热点，但因其药物研发难度大，现阶段进入Ⅲ期临床的药物大都以失败告终。因此，对AD进行多角度的病理机制研究和寻找早期生物检测标记物迫在眉睫。
由于AD的发生、发展是一个动态演变的过程，从最早的Aβ沉积到出现痴呆症状之间的间隔，可以长达20多年，并且是一个不可逆的慢性神经退行性病变过程。针对AD的早期临床诊断和后续治疗是解决AD病症的关键点。目前AD的诊断方法主要是联合诊断，主要包括：神经心理学评估，认知损伤测试；脑部老年斑块和Tau蛋白PET扫描；脑部核磁共振(MRI)和脑脊液(CSF)标志物，Aβ沉积，磷酸化tau蛋白检测等。但是，由于AD早期症状不明显，当对病症做出明确诊断时，患者多到达病程晚期，多数神经元出现死亡，如果能在病人发病早期进行快速诊断或使潜在病人提前发现风险，针对性地进行治疗或预防，能有助于患者病程滞留在轻微智力损伤阶段(mild cognitive impairment，MCI)而减缓恶化，从而保证病人生活质量和减轻社会负担。现阶段对AD的早期分子筛查技术包括正电子发射型计算机断层显像(PET)和脑脊液Aβ分子水平检测等，前者要对受检者注射一定剂量的放射性物质；后者操作损伤大，易造成外科感染。这些诊断技术针对AD早期诊断的可靠性也不太稳定， 因此很难用于AD早期筛查。AD的预防、诊断、治疗与康复是目前世界上公认的难题，对AD早期诊断新的标志物开发及简便的检测手段是未来对AD诊疗的重要方向之一。
发明内容
为了解决现有技术中的问题，本发明旨在提供一种用于早期诊断阿尔茨海默症的生物标志物及其用途。
神经炎症是AD患者脑内主要病理特征之一，炎症过程促进了Aβ病理学和Tau病理学进展。因此，神经炎症在AD疾病发生和发展过程中起着关键作用，针对脑内神经炎症的治疗已经成为现阶段治疗AD的新的热点。而这种靶向调控早期神经炎症的关键分子被视为有潜力的干预AD新的治疗靶点。大量研究表明，血液中的循环免疫细胞在维持中枢神经系统稳态和介导神经系统疾病的免疫反应方面发挥至关重要的作用。神经炎症过程中，脑内激活的小胶质细胞和星形胶质细胞释放多种细胞因子和趋化因子等炎性介质，有助于血脑屏障的通透性增加并允许外周循环免疫细胞的浸润、粘附和迁移，进一步影响脑内抗神经炎症的免疫反应。近期研究发现，AD患者大脑中存在浸润的外周循环的效应CD8 +T细胞，这群细胞不仅可以激活小胶质细胞诱导剧烈的炎症反应，从而进一步加剧AD脑内神经炎症爆发。这一发现证实了外周循环的免疫细胞在AD发生发展中起着免疫监控的重要作用。最新研究表明，在AD患者脑内和AD小鼠模型海马中发现一群适应性外周免疫细胞亚群，它们可以释放炎症因子和细胞毒性分子，促进脑内炎症反应从而导致神经元功能障碍。促炎细胞因子增加、免疫细胞浸润和神经胶质细胞活化是AD中重要的神经炎症反应。
本发明通过检测AD疾病不同阶段的外周血中炎症因子水平、免疫细胞亚群变化与脑内神经炎症严重程度的相关性，从而确定外周血中炎症因子表达水平的改变和免疫细胞亚群数量的改变在AD进程中的指示作用。
本发明的具体技术方案如下：
本发明第一方面提供外周血白细胞介素6、外周血CD8 +T细胞和外周血CD4 +T细胞中的一种或几种作为早期诊断神经退行性疾病的生物标志物的用途。
进一步地，所述神经退行性疾病为阿尔茨海默症。
本发明第二方面提供外周血白细胞介素6、外周血CD8 +T细胞和外周血CD4 +T细胞中的一种或几种在制备神经退行性疾病早期诊断的产品中的用途。
进一步地，所述产品包括：通过酶联免疫吸附、实时荧光定量PCR或RT-PCR检测外周 血白细胞介素6表达水平以诊断神经退行性疾病的产品；和/或通过流式细胞分析或免疫荧光染色检测外周血CD8 +T细胞和/或外周血CD4 +T细胞数量的变化以诊断神经退行性疾病的产品。
进一步地，所述神经退行性疾病为阿尔茨海默症。
本发明第三方面提供外周血白细胞介素6、外周血CD8 +T细胞和外周血CD4 +T细胞中的一种或几种作为神经退行性疾病药物靶点的用途。
进一步地，所述神经退行性疾病为阿尔茨海默症。
本发明第四方面提供一种神经退行性疾病的早期诊断方法，包括如下步骤：
检测外周血中白细胞介素6的表达水平和/或CD8 +T细胞的数量和/或CD4 +T细胞的数量，根据外周血中白细胞介素6表达水平的变化和/或CD8 +T细胞数量的变化和/或CD4 +T细胞数量的变化判断是否罹患神经退行性疾病，根据外周血中白细胞介素6表达上升水平和/或CD4 +T细胞和/或CD8 +T细胞异常情况的严重程度判断神经退行性疾病进程；
当外周血中白细胞介素6的表达水平增多和/或CD8 +T细胞的数量提高和/或CD4 +T细胞的数量减少，则罹患神经退行性疾病。
进一步地，所述早期诊断方法还包括：检测脑脊液中白细胞介素6的表达水平和/或CD8 +T细胞的数量，根据脑脊液中白细胞介素6表达水平的变化和/或CD8 +T细胞数量的变化判断是否罹患神经退行性疾病，根据脑脊液中白细胞介素6表达上升水平和/或CD8 +T细胞异常情况的严重程度判断神经退行性疾病进程；
当脑脊液中白细胞介素6的表达水平增多和/或CD8 +T细胞的数量提高，则罹患神经退行性。
进一步地，根据外周血中白细胞介素6表达水平的变化和CD8 +T细胞数量的变化进行诊断；
当外周血中白细胞介素6的表达水平增多和CD8 +T细胞的数量提高，则罹患神经退行性疾病。
进一步地，根据外周血中白细胞介素6表达水平的变化、CD8 +T细胞数量的变化和CD4 +T细胞数量的变化进行诊断；
当外周血中白细胞介素6的表达水平增多，CD8 +T细胞的数量提高和CD4 +T细胞的数量减少，则罹患神经退行性疾病。
进一步地，根据外周血白细胞介素6表达水平的变化、外周血CD8 +T细胞数量的变化和 脑脊液CD8 +T细胞数量的变化进行诊断；
当外周血白细胞介素6的表达水平增多、外周血CD8 +T细胞的数量提高和脑脊液CD8 +T细胞的数量提高，则罹患神经退行性疾病。
进一步地，所述外周血取自人或小鼠。
进一步地，所述神经退行性疾病为阿尔茨海默症。
本发明第五方面上述用途或上述早期诊断方法在筛选神经退行性疾病治疗药物中的应用。
进一步地，所述神经退行性疾病治疗药物抑制外周血中白细胞介素6的表达和/或减少外周血中CD8 +T细胞的数量和/或增加CD4 +T细胞的数量。
进一步地，所述神经退行性疾病为阿尔茨海默症。
本发明第六方面提供上述用途或上述早期诊断方法在筛选神经退行性疾病的新生物标志物或新药物靶点中的应用。
进一步地，新生物标志物或新药物靶点影响外周血中白细胞介素6表达水平和/或CD8 +T细胞数量和/或CD4 +T细胞数量。
进一步地，所述神经退行性疾病为阿尔茨海默症。
本发明的有益效果为：
本发明通过基于外周循环中免疫细胞和免疫分子的改变实现诊断早期AD，具体提供作为早期诊断AD的标志物炎症因子IL-6、外周循环免疫细胞亚群CD8 +T细胞和辅助性CD4 +T细胞，可以直接对外周血样本进行检测，判断机体的炎症水平，实现AD的早期筛查中。其优势在于，通过检测血液中生物标志物进行AD发生发展的临床诊断不仅降低了诊断成本，而且容易操作，避免了受检者脑内取样过程中感染中枢风险，患者接受度高且比较容易进行疾病的大规模筛查，提高了检测的效率，增加了结果的准确性，具有实际应用的价值。本发明可用于指导临床筛查、AD致病机理的研究、AD治疗药物的筛选以及AD的新生物标志物和潜在的新用药靶点的筛选中，具有广阔的应用前景。
附图说明
图1. 3月龄(3M)、6月龄(6M)、9月龄(9M)和12月龄(12M)野生型小鼠(WT)和APP/PS1小鼠(AD)外周血中IL-6表达量变化(*p<0.05)。
图2. 3月龄(3M)和6月龄(6M)野生型小鼠(WT)和APP/PS1小鼠(AD)外周血 中适应性免疫细胞亚群的改变(*p<0.05)。
图3. 3月龄(3M)和6月龄(6M)野生型小鼠(WT)和APP/PS1小鼠(AD)小鼠的脑组织免疫荧光染色的结果图片(比例尺＝50μm)和不同月龄CD8 +T细胞细胞浸润的统计结果(*p<0.05)。A.脑片在脑图谱中拍摄的位置。B.为不同月龄脑组织切片中小胶质细胞表面标记物Iba1，T细胞表面标记物CD8，细胞核标记物DAPI。C.为不同月龄WT和AD小鼠脑内浸润CD8+T细胞统计结果。
图4. 3月龄(3M)和6月龄(6M)野生型小鼠(WT)和APP/PS1小鼠(AD)脑脊液内IL-6表达水平的结果(*p<0.05)。
图5. 3月龄(3M)和6月龄(6M)野生型小鼠(WT)和APP/PS1小鼠(AD)大脑皮层和海马体内的IL-6基因表达水平的结果(*p<0.05，**p<0.01，***p<0.001)。
具体实施方式
为了更清楚地理解本发明，现参照下列实施例及附图进一步描述本发明。实施例仅用于解释而不以任何方式限制本发明。实施例中，各原始试剂材料均可商购获得，未注明具体条件的实验方法为所属领域熟知的常规方法和常规条件，或按照仪器制造商所建议的条件。
本发明主要在APP/PS1小鼠模型(以下简称AD小鼠模型)进行，AD小鼠模型是模拟AD疾病理想的动物模型之一，广泛应用于AD致病机制的研究。本发明以不同月龄AD小鼠模型作为研究对象，通过脑组织免疫荧光染色技术、总RNA提取技术、qRT-PCR技术、外周血清的酶联免疫吸附实验(ELISA)等，通过对同窝野生型(同窝野生型)和患病组(APP/PS1转基因小鼠，AD)组间对比，得到了外周血中炎症因子IL-6和细胞毒性CD8 +T细胞、辅助性CD4 +T细胞在AD转基因小鼠外周循环发生异常与脑内炎症发生发展相关的明确结论。基于此，本发明提供了外周血中炎症因子IL-6表达水平改变和细胞毒性CD8 +T细胞、辅助性CD4 +T细胞数量变化可作为AD早期诊断分子标志物的可靠证据：3月龄AD小鼠对应病人的病程发展为即将迈入轻微智力损伤(MCI)阶段，6月龄AD小鼠则AD病症特征明确。以下将结合实例对本发明的特征和性能进行进一步的详细描述。
本发明所涉及的材料：
同窝野生型小鼠和APP/PS1小鼠模型来自美国Jackson实验室；
多聚甲醛购自Sigma-aldrich，货号：158127；
包埋剂OCT购自SAKURA，货号：4583；
Iba1一抗购自Wake公司，货号：019-19741；
CD8一抗购自Invitrogen，货号：14-0195-82；
DAPI购自Thermo scientific公司，货号：62248；
荧光二抗购自Thermo scientific；
红细胞裂解液购自BD Biosciences公司，货号：555899；
流式分析使用的抗体均购自BD Biosciences公司，货号依次为：
Ms CD45 FITC 30-F11，货号：553079；
Ms CD3 MolCpx PerCP-Cy5.5 17A2，货号：560527；
Ms CD4 APC-H7 GK1.5，货号：560181；
Ms CD8a PE 53-6.7，货号：553032；
Ms CD19 PE-Cy7 1D3，货号：552854；
Ms CD49b APC DX5，货号：560628；
马血清购自Gibco公司，货号：26050088；
胎牛血清购自Life Technologies公司，货号：16050-122；
DAPI购自Thermo scientific公司，货号：D1306；
DPBS购自Sigma公司，货号：D8662-24*500ML；
Trizol购自invitrogen公司，货号：15596026；
反转录试剂盒购自Thermo scientific，货号K1622；
实时荧光定量PCR试剂盒购自Thermo scientific，货号4368706；
ELISA试剂盒购自R&D，货号：M6000B。
实施例1：外周血中炎症因子IL-6的表达水平检测
本实施例使用ELISA试剂盒，分别对3月龄和6月龄野生型小鼠和APP/PS1小鼠外周血中的白细胞介素6(IL-6)的表达水平进行检测，步骤如下：
1、血清样品采集
将3月龄及6月龄同窝野生型和AD小鼠用异氟烷气体麻醉后，眼底采血法收集小鼠的血液样本至1.5mL的灭菌EP管中，断颈后并用剪刀迅速断头处死小鼠，并按照下述方法分离血清：
将抗凝血样品置于4℃静置4h，待血液凝固后自然析出血清，在4℃下4000rpm离心30min，分离血清，弃去不溶物；
将血清移至新的灭菌EP管，分装后-80℃储存备用。
2、试剂配置
(1)阳性对照配制：用1mL去离子水溶解IL-6阳性对照，充分混匀，备用。
(2)洗涤液配制：用去离子水按1:25稀释至工作浓度。
(3)发光试剂配制：在上机检测前15min，将试剂盒中的发光试剂A和试剂B按照1:1体积混匀，避光保存。
(4)IL-6标准品配制：将试剂盒中提供的5000pg/mL的标准品在新的EP管中用校准稀释剂按照1:10稀释成500pg/mL的标准品，再稀释成浓度分别为250pg/mL、125pg/mL、62.5pg/mL、31.3pg/mL、15.6pg/mL和7.81pg/mL的标准品。
3、ELISA检测
(1)向测试孔中加入50μL测定稀释剂RD1W。
(2)向测试孔中依次加入标准品、对照样品和待测样品，用试剂盒中提供的封口膜封口后室温孵育2h。
(3)孵育结束后，撕下封口膜，弃去液体，每孔中加入400μL洗涤液洗涤检测板，洗涤4次，弃去洗涤液。
(4)向测试孔中加入100μL小鼠IL-6偶联物，封口膜封口后，室温孵育2h。
(5)重复步骤(3)1次。
(6)向测试孔中加入100μL配制的发光试剂，避光室温孵育39min。
(7)加入100μL终止液，轻弹混匀测试板确保充分混匀。
(8)读板：在30min内完成每个孔的光密度检测。
(9)计算：根据试剂盒提供的公式进行浓度定量计算。
4、实验结果
3月龄(3M)、6月龄(6M)、9月龄(9M)和12月龄(12M)的野生型小鼠(WT)和APP/PS1小鼠(AD)外周血血清中的炎症因子IL-6的表达水平如图1所示。由图可知，与WT组小鼠相比，在3月龄AD小鼠的外周血血清中IL-6表达水平显著上升，随着疾病进程的发展，IL-6在外周血血清中出现持续上升的趋势。表明在AD发生早期阶段外周血循环系统参与到AD引起的疾病进程，可以作为早期AD诊断的外周血生物标记物。
实施例2：外周血单个核细胞(Peripheral blood mononuclear cells，PBMCs)的流式细胞分析
本实施例对6月龄和9月龄的野生型小鼠和APP/PS1小鼠的外周血单个核细胞(Peripheral blood mononuclear cells，PBMCs)进行流式细胞分析，步骤如下：
1、高活性的外周血单个核细胞(PBMCs)制备
(1)在200μL抗凝全血中加入3倍体积的红细胞裂解液轻轻混匀，室温静止10min，其间轻混匀2次，裂解红细胞。
(2)在800×g下离心2min，弃上清，收集细胞，用1mLPBS清洗样品1次。
(3)使用500μL缓冲液重悬，300目细胞滤网过滤后，孵育抗体，后上机分析。
2、流式分析
(1)将上述步骤制备的PBMCs细胞悬液用含有2％胎牛血清的DPBS调整细胞密度为5×10 6个/mL。
(2)取40μL细胞悬液加入预先装有50μL荧光标记的特异性抗体的塑料离心管中，再加入50μL灭活正常马血清(按1:20用DPBS稀释)，4℃下孵育30min。
(3)加入2mL含有2％胎牛血清的DPBS充悬混匀细胞洗涤，1000rpm在4℃下离心5min，重复洗涤细胞1次。
(4)加入500μL预冷PBS重悬细胞，准备上机分析。
3、实验结果
基于不同月龄AD外周血中炎症因子IL-6表达水平的变化，本实施例选择AD早期阶段：3月龄(3M)和6月龄(6M)小鼠进行PBMCs T淋巴细胞亚群流式分析，结果如图2。流式结果分析表明，与WT小鼠相比，在6月龄AD小鼠的外周血中，辅助性T细胞(CD4 +T细胞)表达显著降低，细胞毒性T细胞(CD8 +T细胞)显著升高，说明外周循环中的免疫细胞可以对AD脑内的神经炎症发挥免疫调节作用。揭示在AD进程(CD8 +T细胞)可以作为早期AD诊断的外周循环生物标志物。
实施例3：CD8 +T细胞的细胞浸润检测
本实施例使用免疫荧光染色试剂盒，对野生型小鼠和APP/PS1小鼠模型(AD小鼠模型)的脑组织进行CD8、Iba1和DAPI染色，步骤如下：
1、小鼠脑组织切片
(1)麻醉及脑组织灌注取样：向小鼠腹腔注射水合氯醛麻醉，深度麻醉后，固定在手术木板上，置于解剖盘中，后端头取脑，并用多聚甲醛浸泡固定24h。
(2)小鼠的灌注固定：使用4℃的PBS灌注小鼠，每只20mL，后使用4℃的4％多聚 甲醛(称取40g多聚甲醛溶于装有500mL DEPC水的玻璃容器中，持续加热，磁力搅拌至60℃，形成乳白色悬液。用1.0mmol/L的NaOH调节pH为7.0，使溶液呈清亮状，再加入约500mL 2×PBS，充分混匀，过滤后定容至1000mL，4℃保存备用)灌注，每只小鼠20mL，至组织变硬。
(3)取材：小心剥离脑组织，置于15mL离心管中，用4％多聚甲醛(固定剂)后固定24h。
(4)脱水：将多聚甲醛固定好的组织用PBS(清洗液)洗3次，20％蔗糖(脱水剂)脱水至组织沉底，30％蔗糖4℃下脱水过夜。
(5)将包埋剂OCT滴加到标本台，放入恒冷箱切片机内至变白，然后取出，迅速将表面用单面刀片修平。
(6)用安全刀片将标本底部修平后粘附于标本台，然后置入-24℃恒冷箱切片机的冷冻台中，待组织略微发白时用OCT在标本表面涂一薄层，继续冷冻20min。
(7)调好切片厚度后开始切片，切片厚度20μm，切好的片子连续收集，移入含4％多聚甲醛的24孔板。
(8)将切好的片子放4℃保存备用。
2、免疫荧光染色
(1)小心挑出合适位置的切片到预先放有1mL预冷PBS的24孔板中，用预冷PBS洗3次，每次10min。
(2)打孔及封闭：0.2％Triton X-100(PBS稀释)、0.1％BSA及5％马血清(PBS稀释)，室温孵育40min，放置摇床上慢速摇晃。
(3)PBS室温下洗3次，每次5min。
(4)一抗孵育：使用抗体稀释液(PBS中含0.01％BSA和5％马血清)按1:100进行稀释，每孔中加入200μL，4℃慢速摇晃孵育过夜。
(5)回收一抗，PBS室温下洗3次，每次10min。
(6)3％马血清室温下封闭脑片30min。
(7)二抗孵育及DAPI染色：使用PBS按1:500稀释二抗，室温避光孵育2h；DAPI按1:5000稀释储存液，室温孵育15min。
(8)用PBS室温下洗3次，每次15min。
(9)封片：取粘性载玻片，在右侧磨砂面用铅笔标记具体信息，在载玻片中间滴一滴 PBS，沾取切片放于PBS液滴上，吸除PBS溶液，在载玻片中央横铺160μL封片剂，用长条盖玻片盖住切片，避免气泡以及褶皱产生。
(10)平放于避光处晾干。
3、实验结果
3月龄(3M)、6月龄(6M)、9月龄(9M)和12月龄(12M)的野生型小鼠(WT)和APP/PS1小鼠(AD)的染色图片如图3所示。由图可知，在6月龄AD小鼠皮层和海马部位有外周来源的CD8 +T细胞浸润入脑内病灶部位，随着病情发展，9月龄和12月龄AD小鼠脑组织中CD8 +T细胞浸润增多，小胶质细胞激活数目增多，且成聚集状态，而3月龄小鼠没有出现这一现象。这一结果表明，在AD小鼠模型中，CD8 +T细胞介导的神经炎症发生发展在3月龄和6月龄之间或者更早阶段。这说明可将CD8 +T细胞的数目改变可以作为AD的早期标记物。
实施例4:脑脊液中炎症因子IL-6的表达水平检测
1、脑脊液样品采集：
小鼠麻醉后，将头部固定于定向仪上。采集脑脊液时，用湿纱布擦试大鼠颈背部皮肤，剪去背毛，暴露皮肤并消毒，用手术刀沿纵轴切一纵行切口(约1cm)，用剪刀钝性分离颈部背侧肌肉。为避免出血，最深层附着在骨上的肌肉用手术刀背刮开，暴露寰枕膜。由枕骨大孔进针直接抽取脑脊液。抽取完毕后缝合外层肌肉、皮肤。刀口处可撒涂磺胺药粉，防止感染。采完脑脊液后，应注入等量的消毒生理盐水，以保持原来脑脊髓腔的压力。
2、IL-6表达水平检测
本实施例对3月龄(3M)和6月龄(6M)的野生型小鼠(WT)和APP/PS1小鼠(AD)的脑脊液进行ELISA检测，测定随着疾病进程IL-6表达平的变化，实验步骤与实施例1相同。
3、实验结果
3月龄(3M)和(6M)的野生型小鼠(WT)和APP/PS1小鼠(AD)的脑脊液中IL-6表达水平变化如图4。在3月龄和6月龄小鼠的脑脊液中，与WT小鼠相比，AD小鼠在两个月龄中均表现出IL-6表达水平显著升高。说明在AD发生早期阶段IL-6参与到AD引起的疾病进程，可以作为早期AD诊断的脑脊液检测生物标记物。
实施例5：大脑皮层和海马体内炎症因子IL-6的表达水平检测
本实施例使用实时荧光定量PCR试剂盒，分别对3月龄和6月龄野生型小鼠和APP/PS1小鼠的大脑皮层(cortex)和海马体(hippocampus)内的IL-6的表达水平进行检测，步骤如 下：
1、RNA提取
(1)将3月龄及6月龄同窝野生型和AD小鼠用异氟烷(气体)麻醉后，断颈后用剪刀迅速断头处死，将头放于冰上，迅速分离大脑皮质并分离小鼠的大脑皮层以及海马体。将分离到的组织在含有4U/mL的蛋白酶抑制剂和RNA酶抑制剂的DPBS洗涤两次。
(2)匀浆处理：将组织或细胞在液氮中磨碎，每100mg组织加入1mL Trizol(RNA提取试剂)，用匀浆仪进行匀浆处理。
(3)将匀浆样品在室温放置5min，使核酸蛋白复合物完全分离。
(4)每使用1mL Trizol加入0.2mL氯仿，剧烈振荡15s，室温放置3min。
(5)4℃下10000×g离心15min。
(6)把水相转移到新管中，用异丙醇沉淀水相中的RNA，每使用1mL Trizol加入0.5mL异丙醇，室温放置10min。
(7)4℃下10000×g离心10min，在管侧和管底出现胶状沉淀，弃上清。
(8)用75％乙醇洗涤RNA沉淀，每使用1mL Trizol加1mL 75％乙醇，4℃下7500×g离心5min，弃上清。
(9)室温放置干燥5min，加入50μL无RNase的水，用枪头吸打几次，55℃放置10min使RNA溶解，-70℃保存。
2、反转录
使用反转录试剂盒将提取的总RNA反转录成cDNA，步骤如下：
在无RNA酶的离心管中制备反应混合物I，体系如下：
Figure PCTCN2022087570-appb-000001
将上述组分混合后快速离心5s，在70℃孵育5min后，冰浴2min，再按下述体系制备反应混合物II，体系如下：
Figure PCTCN2022087570-appb-000002
Figure PCTCN2022087570-appb-000003
将反应混合物I加入到反应混合物II中，快速混合5s，在70℃孵育5min后，冰浴2min，按一下程序进行反转录：
25℃，5min；42℃，60min；70℃，5min。
得到的cDNA模板置于-20℃保存备用。
3、实时荧光定量PCR
使用实时荧光定量PCR试剂盒对IL-6的表达水平进行检测，反应体系如下：
Figure PCTCN2022087570-appb-000004
其中，正向引物的序列如SEQ ID No.1所示，反向引物的序列如SEQ ID No.2所示。
SEQ ID No.1：ctggggatgtctgtagctca；
SEQ ID No.2：ctgtgaagtctcctctccgg。
将上述组分混合，6000rpm离心1min，按以下程序进行扩增：
预变性：95℃，10min；
循环扩增：95℃，15s；60℃，1min；70℃，1min；循环40次；
形成熔解曲线：95℃，15s；60℃，1min；
整个过程中升温和降温的速率为1.6℃/s。
4、实验结果
由图5可知，在3月龄和6月龄WT小鼠中，同一组中野生型小鼠个体之间细胞因子表达的变化相对比较集中，而AD小鼠中，同一组不同个体之间各个细胞因子表达变化差异比 较大，且IL-6在3月龄和6月龄AD模型小鼠的大脑皮层和海马区基因表达水平显著升高。提示，IL-6在外周和中枢表达具有明显的相关性，进一步证明本发明中发现的外周血中IL-6可以作为早期AD的诊断指标。
显然，上述实施例仅仅是为清楚地说明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。

Claims (20)

  1. 外周血白细胞介素6、外周血CD8 +T细胞和外周血CD4 +T细胞中的一种或几种作为早期诊断神经退行性疾病的生物标志物的用途。
  2. 根据权利要求1所述的用途，其特征在于，所述神经退行性疾病为阿尔茨海默症。
  3. 外周血白细胞介素6、外周血CD8 +T细胞和外周血CD4 +T细胞中的一种或几种在制备神经退行性疾病早期诊断的产品中的用途。
  4. 根据权利要求3所述的用途，其特征在于，所述产品包括：通过酶联免疫吸附、实时荧光定量PCR或RT-PCR检测外周血白细胞介素6表达水平以诊断神经退行性疾病的产品；和/或通过流式细胞分析或免疫荧光染色检测外周血CD8 +T细胞和/或外周血CD4 +T细胞数量的变化以诊断神经退行性疾病的产品。
  5. 根据权利要求3所述的用途，其特征在于，所述神经退行性疾病为阿尔茨海默症。
  6. 外周血白细胞介素6、外周血CD8 +T细胞和外周血CD4 +T细胞中的一种或几种作为神经退行性疾病药物靶点的用途。
  7. 根据权利要求6所述的用途，其特征在于，所述神经退行性疾病为阿尔茨海默症。
  8. 一种神经退行性疾病的早期诊断方法，其特征在于，包括如下步骤：
    检测外周血中白细胞介素6的表达水平和/或CD8 +T细胞的数量和/或CD4 +T细胞的数量，根据外周血中白细胞介素6表达水平的变化和/或CD8 +T细胞数量的变化和/或CD4 +T细胞数量的变化判断是否罹患神经退行性疾病，根据外周血中白细胞介素6表达上升水平和/或CD4 +T细胞和/或CD8 +T细胞异常情况的严重程度判断神经退行性疾病进程；
    当外周血中白细胞介素6的表达水平增多和/或CD8 +T细胞的数量提高和/或CD4 +T细胞的数量减少，则罹患神经退行性疾病。
  9. 根据权利要求8所述的早期诊断方法，其特征在于，所述早期诊断方法还包括：检测脑脊液中白细胞介素6的表达水平和/或CD8 +T细胞的数量，根据脑脊液中白细胞介素6表达水平的变化和/或CD8 +T细胞数量的变化判断是否罹患神经退行性疾病，根据脑脊液中白细胞介素6表达上升水平和/或CD8 +T细胞异常情况的严重程度判断神经退行性疾病进程；
    当脑脊液中白细胞介素6的表达水平增多和/或CD8 +T细胞的数量提高，则罹患神经退行性。
  10. 根据权利要求8所述的早期诊断方法，其特征在于，根据外周血中白细胞介素6表达水平的变化和CD8 +T细胞数量的变化进行诊断；
    当外周血中白细胞介素6的表达水平增多和CD8 +T细胞的数量提高，则罹患神经退行性疾病。
  11. 根据权利要求8所述的早期诊断方法，其特征在于，根据外周血中白细胞介素6表达水平的变化、CD8 +T细胞数量的变化和CD4 +T细胞数量的变化进行诊断；
    当外周血中白细胞介素6的表达水平增多，CD8 +T细胞的数量提高和CD4 +T细胞的数量减少，则罹患神经退行性疾病。
  12. 根据权利要求9所述的早期诊断方法，其特征在于，根据外周血白细胞介素6表达水平的变化、外周血CD8 +T细胞数量的变化和脑脊液CD8 +T细胞数量的变化进行诊断；
    当外周血白细胞介素6的表达水平增多、外周血CD8 +T细胞的数量提高和脑脊液CD8 +T细胞的数量提高，则罹患神经退行性疾病。
  13. 根据权利要求8或9所述的早期诊断方法，其特征在于，所述外周血取自人或小鼠。
  14. 根据权利要求8或9所述的早期诊断方法，其特征在于，所述神经退行性疾病为阿尔茨海默症。
  15. 权利要求1所述用途、权利要求3所述用途、权利要求6所述用途或权利要求8所述早期诊断方法在筛选神经退行性疾病治疗药物中的应用。
  16. 根据权利要求15所述的应用，其特征在于，所述神经退行性疾病治疗药物抑制外周血中白细胞介素6的表达和/或减少外周血中CD8 +T细胞的数量和/或增加CD4 +T细胞的数量。
  17. 根据权利要求15所述的应用，其特征在于，所述神经退行性疾病为阿尔茨海默症。
  18. 权利要求1所述用途、权利要求3所述用途、权利要求6所述用途或权利要求8所述早期诊断方法在筛选神经退行性疾病的新生物标志物或新药物靶 点中的应用。
  19. 根据权利要求18所述的应用，其特征在于，新生物标志物或新药物靶点影响外周血中白细胞介素6表达水平和/或CD8 +T细胞数量和/或CD4 +T细胞数量。
  20. 根据权利要求18所述的应用，其特征在于，所述神经退行性疾病为阿尔茨海默症。
PCT/CN2022/087570 2022-04-19 2022-04-19 一种用于早期诊断阿尔茨海默症的生物标志物及其用途 Ceased WO2023201511A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/087570 WO2023201511A1 (zh) 2022-04-19 2022-04-19 一种用于早期诊断阿尔茨海默症的生物标志物及其用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/087570 WO2023201511A1 (zh) 2022-04-19 2022-04-19 一种用于早期诊断阿尔茨海默症的生物标志物及其用途

Publications (1)

Publication Number Publication Date
WO2023201511A1 true WO2023201511A1 (zh) 2023-10-26

Family

ID=88418953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/087570 Ceased WO2023201511A1 (zh) 2022-04-19 2022-04-19 一种用于早期诊断阿尔茨海默症的生物标志物及其用途

Country Status (1)

Country Link
WO (1) WO2023201511A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117805391A (zh) * 2023-12-25 2024-04-02 武汉科技大学 检测早期轻度认知障碍和/或阿尔兹海默症的生物标志物及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200341011A1 (en) * 2017-11-17 2020-10-29 Edward J. Goetzl Astrocyte exosome complement-based assay for neuroinflammation in alzheimer's disease and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200341011A1 (en) * 2017-11-17 2020-10-29 Edward J. Goetzl Astrocyte exosome complement-based assay for neuroinflammation in alzheimer's disease and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BONOTIS, KONSTANTINOS ET AL.: "Systemic Immune Aberrations in Alzheimer's Disease Patients.", J NEUROIMMUNOL, vol. 193, no. 1-2, 26 November 2007 (2007-11-26), XP022414037, DOI: 10.1016/j.jneuroim.2007.10.020 *
FANI LANA, GEORGAKIS MARIOS K., IKRAM M. ARFAN, MALIK RAINER, DICHGANS MARTIN: "Circulating biomarkers of immunity and inflammation, risk of Alzheimer’s disease, and hippocampal volume: a Mendelian randomization study", TRANSLATIONAL PSYCHIATRY, vol. 11, no. 1, XP093103006, DOI: 10.1038/s41398-021-01400-z *
GUO, ZHENHUA ET AL.: "Study of CD 3, CD 4, CD 8 and CD 4/ CD 8 levels in the Serum of Alzheimer's Patients and Their Significance", ZHONGFENG YU SHENJING JIBING ZAZHI = JOURNAL OF APOPLEXY AND NERVOUS DISEASES, JILIN DAXUE BAIQIUEN DI-1 YIYUAN ZHUANHUA YIXUE YANJIUYUAN, CN, vol. 22, no. 5, 31 October 2005 (2005-10-31), CN , pages 464, XP009549862, ISSN: 1003-2754 *
LIN QIAO, MENG XIU-JUN, REN YU-FENG, LI MING, FANG QIANG, LIU JUN, ZHANG YUAN-YUAN: "Different Levels of Cognition on the Expression of Helper T Cell in Alzheimer Patients", SHANXI MEDICAL JOURNAL, vol. 42, no. 4, 30 April 2013 (2013-04-30), pages 366 - 368, XP093103005 *
WU, YA-YING ET AL.: "Alterations of the Neuroinflammatory Markers IL -6 and TRAIL in Alzheimer's Disease.", DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, vol. 5, no. 3, 24 November 2015 (2015-11-24), pages 424 - 434, XP009549882, ISSN: 1664-5464, DOI: 10.1159/000439214 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117805391A (zh) * 2023-12-25 2024-04-02 武汉科技大学 检测早期轻度认知障碍和/或阿尔兹海默症的生物标志物及应用

Similar Documents

Publication Publication Date Title
Unger et al. Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice
JP2021192036A (ja) Ａｌｓ関連ジアミノ酸リピート含有タンパク質
Zuo et al. Age-dependent gray matter demyelination is associated with leptomeningeal neutrophil accumulation
CN102933966A (zh) 阿尔茨海默病的新型诊断制剂
das Neves et al. Meningeal lymphatic function promotes oligodendrocyte survival and brain myelination
Xiang et al. Neutrophil extracellular traps and neutrophil extracellular traps-related genes are involved in new-onset atrial fibrillation in LPS-induced sepsis
Ye et al. Nogo receptor-Fc delivered by haematopoietic cells enhances neurorepair in a multiple sclerosis model
CN116953247A (zh) 一种用于早期诊断阿尔茨海默症的生物标志物及其用途
WO2023201511A1 (zh) 一种用于早期诊断阿尔茨海默症的生物标志物及其用途
JP2014132863A (ja) 神経変性疾患バイオマーカー
CN118389673B (zh) Trem2基因在制备诊断足细胞损伤的标志物中的应用
JP4933159B2 (ja) アルツハイマー病の診断方法
CN114774534B (zh) Mmp19作为肾脏早期损伤相关的生物标志物在早期诊断肾损伤中的应用
JP2013007724A (ja) 筋ジストロフィーの病態及び治療評価のための分子マーカー
Ren et al. TIGAR attenuates intervertebral disc degeneration via autophagy-mediated Keap1 degradation and Nrf2 nuclear translocation to suppress nucleus pulposus pyroptosis
JP7824649B2 (ja) 胎児発育不全に対する定量的評価指標
CN118294666A (zh) 一种生物标志物及其在帕金森氏病中的应用
CN115537459A (zh) 一种阿尔茨海默症的标记物及其应用
WO2023101599A2 (en) A method of sorting a heterogenous macrophage population
US20250290935A1 (en) Marker of alzheimer&#39;s disease and use thereof
WO2025123283A1 (zh) 检测试剂在制备用于诊断或者监测ad的诊断工具中的应用
CN120195401A (zh) 检测试剂在制备用于诊断或者监测ad的诊断工具中的应用
Hemmer et al. Youth-associated protein TIMP2 alters microglial state and function in the context of aging
JP2016198021A (ja) 筋萎縮性側索硬化症の検出を補助する方法及び治療剤
KR20260001590A (ko) 뇌졸중 또는 뇌졸중 후 신경계 손상 진단용, 뇌졸중 또는 뇌졸중 후 신경계 손상 중증도 진단용, 및 뇌졸중 예후 예측용 바이오 마커 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22937749

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22937749

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 22937749

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 10/04/2025)

122 Ep: pct application non-entry in european phase

Ref document number: 22937749

Country of ref document: EP

Kind code of ref document: A1